iPSC-to-TEP Differentiation Composition Without Animal Implantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating functional thymic epithelial cells (TECs) from human pluripotent stem cells (hPSCs) are inefficient and require animal implantation, limiting their use in clinical applications and therapies.
Innovation Solution
A specific combination of growth factors, including Activin A, BMP4, CHIR99021, EGF, FGF 8, FGF 10, IGF1, LY364947, Noggin, retinoic acid, and Y-27632, is used to differentiate induced pluripotent stem cells (iPSCs) into functional thymic epithelial progenitors (TEPs) through a sequential incubation process over 14 days, enabling efficient in vitro production of TEPs that can mature into TECs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for generating functional TECs from hPSCs are used, then TECs can be produced, but the process requires animal implantation and has low efficiency
Solution Approach 1:
The invention extracts and eliminates the requirement for animal implantation from the TEC generation process. By developing a complete in vitro differentiation protocol using specific growth factor combinations (Activin A, BMP4, FGF8, retinoic acid, Noggin, CHIR99021), the method removes the animal model dependency while maintaining TEC functionality, thereby resolving the contradiction between productivity and device complexity
Solution Approach 2:
The invention applies parameter changes by optimizing the concentrations and sequential timing of growth factors (Activin A at 100 ng/mL, BMP4 at 50 ng/mL, FGF8 at 10 ng/mL, retinoic acid at 1 μM, Noggin at 100 ng/mL, CHIR99021 at 3 μM) during differentiation stages. This precise parameter control enables efficient TEC generation in vitro without animal implantation, simultaneously improving productivity and eliminating procedural complexity
2Object-affected harmful factors
If therapeutic interventions are applied to treat cancer, then cancer treatment is achieved, but T cell mediated immune reconstitution is impaired
Solution Approach 1:
The invention applies preliminary action by generating functional TECs in vitro before bone marrow transplantation. These pre-generated TECs are then transplanted to establish a functional thymus microenvironment that supports T cell development, thereby preventing the impairment of T cell mediated immune reconstitution that normally occurs after ablative chemotherapy or radiotherapy for cancer treatment
3Quantity of substance
If TECs are expanded from post-natal thymi, then TEC supply is increased, but reliable expansion methods have been elusive
Solution Approach 1:
The invention segments the TEC generation process into distinct differentiation stages (day 0-3: Activin A and BMP4 for definitive endoderm; day 3-6: FGF8 and retinoic acid for foregut specification; day 6-10: Noggin and CHIR99021 for thymic progenitor formation; day 10-14: maturation cues) with specific growth factor combinations at each stage. This segmented approach enables reliable TEC expansion from hPSCs by controlling the differentiation journey step-by-step, resolving the contradiction between quantity and ease of manufacture
Data Source
AI summary
The use of a composition, which includes the following compounds: Activin A, BMP4, CHIR99, EGF, FGF 8, FGF 10, IGF1, LY3, Noggin, retinoic acid and Y27, for implementing a differentiation process, preferably in vitro or ex vivo, of an induced pluripotent stem cell or iPSc, into a functional thymic epithelial progenitor or TEP.